BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• 

  Gene editing

  Lilly Leans Into Hearing Loss in $1.12B+ Gene Editing Pact With Seamless

  The deal will help bolster Eli Lilly’s growing hearing loss portfolio, which is anchored by the gene therapy AK-OTOF.

  January 28, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

  January 28, 2026

   · 

  7 min read
• Press Releases

  Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

  January 28, 2026

   · 

  6 min read
• Press Releases

  Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

  January 28, 2026

   · 

  12 min read
• Press Releases

  BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

  January 28, 2026

   · 

  6 min read
• Press Releases

  REVEAL GENOMICS Aligns Founder Leadership With Priorities to Support Long-term Growth, Scientific Excellence, and Global Partnerships

  January 28, 2026

   · 

  4 min read
• Press Releases

  Qlaris Bio Appoints Robert Warner to Board of Directors

  January 28, 2026

   · 

  2 min read
• Press Releases

  Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention

  January 28, 2026

   · 

  4 min read
• Press Releases

  Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

  January 28, 2026

   · 

  7 min read
• Press Releases

  ABLi Therapeutics Completes Collaboration Agreement with The Michael J. Fox Foundation to include Risvodetinib in Path to Prevention Platform Trial

  January 28, 2026

   · 

  4 min read